Vitamin D may play a role in prostate cancer disparities, Cedars-Sinai researchers find

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with European American men, research from Cedars-Sinai Cancer suggests. The multi-institutional study, published in Cancer Research Communications, a journal of the American Association for Cancer Research, could pave the way for revised nutritional guidelines.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.
Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login